Amyndas Pharmaceuticals
  • Home
  • About
    • What We Do
    • Founder’s Bio
    • Management
  • Research & Development
    • Our Focus
    • Our Pipeline
    • Clinical Trials
    • Technology
    • Selected Publications
    • Notes on Targeted Conditions
  • News
  • Contact Us
  • LinkedIn
  • Twitter
  • Home
  • About
    • What We Do
    • Founder’s Bio
    • Management
  • Research & Development
    • Our Focus
    • Our Pipeline
    • Clinical Trials
    • Technology
    • Selected Publications
    • Notes on Targeted Conditions
  • News
  • Contact Us
  • LinkedIn
  • Twitter

Conjugation to albumin-binding molecule tags as a strategy to improve both efficacy and pharmacokinetic properties of the complement inhibitor compstatin

on July 23, 2014

Highlights:

Authors

Huang Y, Reis ES, Knerr PJ, van der Donk WA, Ricklin D, Lambris JD.

 

Reference

ChemMedChem. 2014 Oct;9(10):2223-6. doi: 10.1002/cmdc.201402212. Epub 2014 Jul 23.

 

Source

www.ncbi.nlm.nih.gov

 

Latest News

  • Review: Compstatins: the dawn of clinical C3-targeted complement inhibition

  • JCI Video: Complement C3 Inhibitor AMY-101 in Adults with Periodontal Inflammation – Clinical Trial

  • Forsyth Dentech 2021: Presentation by Amyndas’ Managing Director Dr. Yancopoulou

  • JCI: Phase 2a clinical trial of complement C3 inhibitor AMY-101 in adults with periodontal inflammation

 

Latest Publications

  • Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis

  • Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy

  • The first case of COVID-19 treated with the complement C3 inhibitor AMY-101

  • Complement as a target in COVID-19?

 
 

Copyright © 2022 Amyndas Pharmaceuticals. All Rights Reserved.